Clinical Research Directory
Browse clinical research sites, groups, and studies.
Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France
Sponsor: Alterity Therapeutics
Summary
This multicenter open-label extension study conducted in France is designed to provide ATH434 orally BID to eligible patients who completed the Phase 2 study ATH434-201, and who may benefit from this treatment according to the evaluation by the Investigator.
Official title: Open-Label Extension Study to Provide Access to ATH434 in Patients With Multiple System Atrophy
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
5
Start Date
2026-07
Completion Date
2029-07
Last Updated
2026-07-28
Healthy Volunteers
No
Conditions
Interventions
ATH434
ATH434 75 mg tablets administered orally twice daily (BID).
Locations (4)
Hôpital Pierre-Paul Riquet
Toulouse, Midi-Pyrenees, France
Centre Hospitalier Universitaire de Bordeaux
Bordeaux, New Aquitaine, France
Hôpital de la Timone
Marseille, Provence-Alpes-Côte d'Azur Region, France
Hôpital Universitaire Pitié Salpêtrière
Paris, Île-de-France Region, France